Halozyme Therapeutics: Q1 Earnings Insights - Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics HALO reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:01 PM.

Here's what investors need to know about the announcement.

Halozyme Therapeutics missed estimated earnings by 2.08%, reporting an EPS of $0.47 versus an estimate of $0.48.

Revenue was up $44.86 million from the same period last year.

Last quarter the company beat on EPS by $0.01 which was followed by a 0.85% increase in the share price the next day.

Here's a look at Halozyme Therapeutics's past performance:

Quarter	Q4 2022	Q3 2022	Q2 2022	Q1 2022
EPS Estimate	0.47	0.51	0.50	0.49
EPS Actual	0.48	0.74	0.53	0.47
Revenue Estimate	192.05M	191.10M	138.78M	128.25M
Revenue Actual	181.50M	208.98M	152.37M	117.28M

To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.